These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 16936159

  • 1. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS, Shankar RR, Shankar S, Shen C, Brizendine E, Baron A, McGill J.
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S, Nakamura K, Takeuchi M.
    Med Hypotheses; 2005 Sep; 65(1):152-4. PubMed ID: 15893133
    [Abstract] [Full Text] [Related]

  • 3. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
    Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB.
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
    [Abstract] [Full Text] [Related]

  • 4. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
    Hermanns N, Burkert A, Haak T.
    Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):310-4. PubMed ID: 15216448
    [Abstract] [Full Text] [Related]

  • 5. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
    Rosak C, Haupt E, Walter T, Werner J.
    Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
    [Abstract] [Full Text] [Related]

  • 6. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C, Hofmann U, Paulwitz O.
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [Abstract] [Full Text] [Related]

  • 7. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
    Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M.
    Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 9. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose.
    Abdul-Ghani MA, Williams K, DeFronzo R, Stern M.
    Diabetes Care; 2006 Jul; 29(7):1613-8. PubMed ID: 16801587
    [Abstract] [Full Text] [Related]

  • 10. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
    Pistrosch F, Schaper F, Passauer J, Koehler C, Bornstein SR, Hanefeld M.
    Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
    [Abstract] [Full Text] [Related]

  • 11. Use of acarbose for eliminating the interval between meal consumption and insulin injection in patients with Type 1 diabetes.
    Koch HH, Wudy A, Eberlein G, Quast C.
    Diabetes Nutr Metab; 1999 Jun; 12(3):195-201. PubMed ID: 10554902
    [Abstract] [Full Text] [Related]

  • 12. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E.
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [Abstract] [Full Text] [Related]

  • 13. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A.
    Med Klin (Munich); 2003 Oct 15; 98 Suppl 1():7-11. PubMed ID: 14694835
    [Abstract] [Full Text] [Related]

  • 14. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec 15; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 15. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study.
    Hanefeld M, Schaper F, Koehler C, Bergmann S, Ugocsai P, Stelzer J, Schmitz G.
    Horm Metab Res; 2009 Feb 15; 41(2):132-6. PubMed ID: 19214923
    [Abstract] [Full Text] [Related]

  • 16. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP.
    Diabetes Obes Metab; 2007 Mar 15; 9(2):186-93. PubMed ID: 17300594
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep 15; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 18. Insulin resistance, beta-cell function, and glucose tolerance in Brazilian adolescents with obesity or risk factors for type 2 diabetes mellitus.
    da Silva RC, Miranda WL, Chacra AR, Dib SA.
    J Diabetes Complications; 2007 Sep 15; 21(2):84-92. PubMed ID: 17331856
    [Abstract] [Full Text] [Related]

  • 19. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
    Azuma K, Toyofuku Y, Iesaki T, Otsuka A, Tanaka A, Mita T, Hirose T, Tanaka Y, Daida H, Kawamori R, Watada H.
    Biochem Biophys Res Commun; 2006 Jun 30; 345(2):688-93. PubMed ID: 16696939
    [Abstract] [Full Text] [Related]

  • 20. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP.
    Diabetes Obes Metab; 2008 Dec 30; 10(12):1212-20. PubMed ID: 18476982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.